Quercetin for chronic prostatitis/chronic pelvic pain syndrome

Urologic Clinics of North America

Volumn 38, Issue 3, 2011, Pages 279-284

  Shoskes, Daniel A ^a   Nickel, J Curtis ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Chronic pelvic pain syndrome; Phytotherapy; Prostatitis; Quercetin

Indexed keywords

ANTIINFLAMMATORY AGENT; CURCUMIN; PLACEBO; POLLEN EXTRACT; PROSTA Q; Q UROL; QUERCETIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APHTHOUS STOMATITIS; ARTHRALGIA; BACTERIAL INFECTION; CHRONIC PROSTATITIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FAMILIAL COLON POLYPOSIS; HUMAN; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PELVIS PAIN SYNDROME; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; HUMANS; MALE; PROSTATITIS; QUERCETIN;

EID: 79960623420     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.05.003     Document Type: Review

References (49)

1. Drach G.W., Fair W.R., Meares E.M., et al. Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia?. J Urol 1978, 120(2):266.
2. Meares E.M., Stamey T.A. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968, 5:492-518.
3. Kiyota H., Onodera S., Ohishi Y., et al. Questionnaire survey of Japanese urologists concerning the diagnosis and treatment of chronic prostatitis and chronic pelvic pain syndrome. Int J Urol 2003, 10:636-642.
4. Nickel J.C., Shoskes D., Wang Y., et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome?. J Urol 2006, 176:119-124.
5. Krieger J.N., Nyberg L.J., Nickel J.C. NIH consensus definition and classification of prostatitis. JAMA 1999, 282(3):236-237.
6. Nickel J.C., Nyberg L.M., Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology 1999, 54:229-233.
7. Turner J.A., Ciol M.A., Von Korff M., et al. Healthcare use and costs of primary and secondary care patients with prostatitis. Urology 2004, 63:1031-1035.
8. Clemens J.Q., Markossian T., Calhoun E.A. Comparison of economic impact of chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis/painful bladder syndrome. Urology 2009, 73:743-746.
9. McNaughton Collins M., Fowler F.J.J., Elliott D.B., et al. Diagnosing and treating chronic prostatitis: do urologists use the four-glass test?. Urology 2000, 55:403-407.
10. Shoskes D.A., Shahed A.R. Detection of bacterial signal by 16S rRNA polymerase chain reaction in expressed prostatic secretions predicts response to antibiotic therapy in men with chronic pelvic pain syndrome. Tech Urol 2000, 6:240-242.
11. John H., Maake C., Barghorn A., et al. Immunological alterations in the ejaculate of chronic prostatitis patients: clues for autoimmunity. Andrologia 2003, 35:294-299.
12. Shahed A.R., Shoskes D.A. Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. J Urol 2001, 166:1738-1741.
13. Basyigit I., Yildiz F., Ozkara S.K., et al. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother 2004, 38:1400-1405.
14. Westesson K.E., Shoskes D.A. Chronic prostatitis/chronic pelvic pain syndrome and pelvic floor spasm: can we diagnose and treat?. Curr Urol Rep 2010, 11:261-264.
15. Phillips S.A., Olson E.B., Lombard J.H., et al. Chronic intermittent hypoxia alters NE reactivity and mechanics of skeletal muscle resistance arteries. J Appl Physiol 2006, 100:1117-1123.
16. Shoskes D.A., Nickel J.C., Rackley R.R., et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis 2009, 12:177-183.
17. Shoskes D.A., Katz E. Multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep 2005, 6:296-299.
18. Dell J.R., Butrick C.W. Multimodal therapy for painful bladder syndrome/interstitial cystitis. J Reprod Med 2006, 51:253-260.
19. Magri V., Wagenlehner F., Perletti G., et al. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. J Urol 2010, 184:2339-2345.
20. Shoskes D.A., Nickel J.C., Dolinga R., et al. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 2009, 73:538-542. [discussion: 542-3].
21. Nickel J.C., Shoskes D. Phenotypic approach to the management of chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep 2009, 10:307-312.
22. Nickel J.C., Shoskes D., Irvine-Bird K. Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management. J Urol 2009, 182:155-160.
23. Hedelin H.H. Evaluation of a modification of the UPOINT clinical phenotype system for the chronic pelvic pain syndrome. Scand J Urol Nephrol 2009, 43:373-376.
24. Balavoine G.G., Geletii Y.V. Peroxynitrite scavenging by different antioxidants. Part I: convenient assay. Nitric Oxide 1999, 3:40-54.
25. Terao J. Dietary flavonoids as antioxidants. Forum Nutr 2009, 61:87-94.
26. Chirumbolo S. The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflamm Allergy Drug Targets 2010, 9:263-285.
27. Bobe G., Albert P.S., Sansbury L.B., et al. Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res (Phila) 2010, 3:764-775.
28. Lee S., Kim Y.J., Kwon S., et al. Inhibitory effects of flavonoids on TNF-alpha-induced IL-8 gene expression in HEK 293 cells. BMB Rep 2009, 42:265-270.
29. Chuang C.C., Martinez K., Xie G., et al. Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-{alpha}-mediated inflammation and insulin resistance in primary human adipocytes. Am J Clin Nutr 2010, 92:1511-1521.
30. Huang R.Y., Yu Y.L., Cheng W.C., et al. Immunosuppressive effect of quercetin on dendritic cell activation and function. J Immunol 2010, 184:6815-6821.
31. He L., Wang Y., Long Z., et al. Clinical significance of IL-2, IL-10, and TNF-alpha in prostatic secretion of patients with chronic prostatitis. Urology 2010, 75(3):654-657.
32. Valerio D.A., Georgetti S.R., Magro D.A., et al. Quercetin reduces inflammatory pain: inhibition of oxidative stress and cytokine production. J Nat Prod 2009, 72:1975-1979.
33. Hollman P.C., Katan M.B. Bioavailability and health effects of dietary flavonols in man. Arch Toxicol Suppl 1998, 20:237-248.
34. Hertog M.G., Feskens E.J., Hollman P.C., et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993, 342:1007-1011.
35. Kyle J.A., Sharp L., Little J., et al. Dietary flavonoid intake and colorectal cancer: a case-control study. Br J Nutr 2010, 103:429-436.
36. McCann S.E., Ambrosone C.B., Moysich K.B., et al. Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr Cancer 2005, 53:33-41.
37. Hamdy A.A., Ibrahem M.A. Management of aphthous ulceration with topical quercetin: a randomized clinical trial. J Contemp Dent Pract 2010, 11:E009-E016.
38. Egert S., Wolffram S., Bosy-Westphal A., et al. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 2008, 138:1615-1621.
39. Egert S., Bosy-Westphal A., Seiberl J., et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr 2009, 102:1065-1074.
40. Cruz-Correa M., Shoskes D.A., Sanchez P., et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006, 4:1035-1038.
41. Shoskes D., Lapierre C., Cruz-Correa M., et al. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation 2005, 80:1556-1559.
42. Shoskes D.A., Zeitlin S.I., Shahed A., et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999, 54:960-963.
43. Penna G., Mondaini N., Amuchastegui S., et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007, 51:524-533. [discussion: 533].
44. Shahed A.R., Shoskes D.A. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome: correlation with gram positive bacterial growth and treatment response. J Androl 2000, 21:669-675.
45. Shoskes D.A., Albakri Q., Thomas K., et al. Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response. J Urol 2002, 168:331-335.
46. Plaper A., Golob M., Hafner I., et al. Characterization of quercetin binding site on DNA gyrase. Biochem Biophys Res Commun 2003, 306:530-536.
47. Shoskes D.A., Nickel J.C., Kattan M.W. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology 2010, 75:1249-1253.
48. Pontari M.A., McNaughton-Collins M., O'leary M.P., et al. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int 2005, 96:559-565.
49. Shoskes D., Prots D., Karns J., et al. Greater endothelial dysfunction and arterial stiffness in men with chronic prostatitis/chronic pelvic pain syndrome-a possible link to cardiovascular disease. J Urol 2011, 185(4 Suppl):e572. [abstract: 1428].